UBS Group
PRLD icon

UBS Group’s Prelude Therapeutics PRLD Stock Holding History

UBS Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Buy
64,505
+62,648
+3,374% +$164K ﹤0.01% 6584
2025
Q4 		$5.38K Sell
1,857
-2,314
-55% -$3.9K ﹤0.01% 8690
2025
Q3 		$6.01K Sell
4,171
-100,033
-96% -$100K ﹤0.01% 8810
2025
Q2 		$84.3K Buy
104,204
+8,048
+8% +$6.97K ﹤0.01% 7375
2025
Q1 		$73.8K Buy
96,156
+28,766
+43% +$26.8K ﹤0.01% 7288
2024
Q4 		$85.9K Buy
67,390
+60,374
+861% +$80.1K ﹤0.01% 6968
2024
Q3 		$14.5K Sell
7,016
-3,918
-36% -$18.1K ﹤0.01% 7543
2024
Q2 		$41.7K Sell
10,934
-4,721
-30% -$19.2K ﹤0.01% 6833
2024
Q1 		$74.2K Sell
15,655
-4,218
-21% -$16.4K ﹤0.01% 6344
2023
Q4 		$84.9K Buy
19,873
+12,465
+168% +$37.9K ﹤0.01% 6274
2023
Q3 		$22.9K Buy
7,408
+516
+7% +$1.94K ﹤0.01% 6739
2023
Q2 		$31K Buy
6,892
+5,912
+603% +$35.3K ﹤0.01% 6702
2023
Q1 		$5.59K Sell
980
-57
-5% -$348 ﹤0.01% 8018
2022
Q4 		$6.26K Buy
1,037
+969
+1,425% +$6.21K ﹤0.01% 9059
2022
Q3 		$0 Sell
68
-2,638
-97% -$17.8K ﹤0.01% 10794
2022
Q2 		$14K Buy
2,706
+2,523
+1,379% +$12.8K ﹤0.01% 7415
2022
Q1 		$1K Sell
183
-1,755
-91% -$16.1K ﹤0.01% 9903
2021
Q4 		$23K Sell
1,938
-35,063
-95% -$570K ﹤0.01% 7682
2021
Q3 		$1.16M Buy
37,001
+29,433
+389% +$953K ﹤0.01% 4066
2021
Q2 		$216K Sell
7,568
-14,768
-66% -$526K ﹤0.01% 5285
2021
Q1 		$968K Buy
22,336
+19,755
+765% +$1.31M ﹤0.01% 4283
2020
Q4 		$185K Buy
2,581
+1,158
+81% +$57.6K ﹤0.01% 5284
2020
Q3 		$43K Buy
+1,423
New +$40.2K ﹤0.01% 5755

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group's PRLD Position: Q1 2026 in Review

UBS Group increased its Prelude Therapeutics (PRLD) stake by 3,374% in Q1 2026, buying an estimated $164K and bringing the position to 64,505 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #6584.

UBS Group first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.16M in Q3 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • UBS Group held 64,505 shares of Prelude Therapeutics worth $221K as of Q1 2026.
  • UBS Group bought 62,648 Prelude Therapeutics shares in Q1 2026, an estimated $164K.
  • Prelude Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6584 holding.
  • UBS Group first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • UBS Group's Prelude Therapeutics position peaked at $1.16M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.